Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | BPTF | Q12830 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30488561 | 1.00 | TLR8 (0.43) | TLR8LMNASMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL11632865 | 0.77 | BPTF (0.39) | TLR8LMNASMN1; SMN2BPTF | |
| SCHEMBL18563080 | 0.71 | TLR8 (0.31) | TLR8CYP11B2 | |
| SCHEMBL8820190 | 0.71 | TLR8 (0.54) | TLR8LMNASMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL30488536 | 0.71 | CA12 (0.37) | LMNASMN1; SMN2BPTF | |
| SCHEMBL18502841 | 0.71 | CA12 (0.37) | LMNASMN1; SMN2BPTF | |
| SCHEMBL30150121 | 0.70 | TLR8 (0.52) | TLR8LMNASMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL28930700 | 0.70 | TLR8 (0.52) | TLR8LMNASMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL30989714 | 0.68 | CYP11B1 (0.31) | CYP11B2 | |
| SCHEMBL25314029 | 0.68 | CYP11B1 (0.31) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152584-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-15 | — | — | US | disclosed |
| EP-4461729-A1 | ANTIGEN BINDING PROTEIN TARGETING MSLN AND USE THEREOF | Transthera Sciences (Nanjing), Inc. (CN) | 2024-11-13 | — | — | EP | disclosed |
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-117222626-A | Substituted triazine compounds | 安斯泰来制药株式会社 | 2023-12-12 | — | — | CN | disclosed |
| CN-116669727-A | Triazole-pyridinyl substituted azacyclohexylacetic acid compounds as LPA receptor antagonists | 唯久生物有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023131277-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131277-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-07-13 | — | — | WO | disclosed |
| CN-116410140-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-07-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152584-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | NLRP3, NLRP1, PYCARD | TLR8 76/4885LMNA 915/4885SMN1; SMN2 4407/4885 |
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | TLR8 155/4885LMNA 2265/4885SMN1; SMN2 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.